|
1
|
World Health Organization (WHO), . Global
report on diabetes 2016. WHO; Geneva: 2016, http://www.who.int
|
|
2
|
Magnusson I, Rothman DL, Katz LD, Shulman
RG and Shulman GI: Increased rate of gluconeogenesis in type-ii
diabetes-mellitus-a C-13 nuclear-magnetic-resonance study. J Clin
Invest. 90:1323–1327. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Basu R, Chandramouli V, Dicke B, Landau B
and Rizza R: Obesity and type 2 diabetes impair insulin-induced
suppression of glycogenolysis as well as gluconeogenesis. Diabetes.
54:1942–1948. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Leite NC, Salles GF, Araujo AL,
Villela-Nogueira CA and Cardoso CR: Prevalence and associated
factors of non-alcoholic fatty liver disease in patients with
type-2 diabetes mellitus. Liver Int. 29:113–119. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Targher G, Bertolini L, Padovani R,
Rodella S, Tessari R, Zenari L, Day C and Arcaro G: Prevalence of
nonalcoholic fatty liver disease and its association with
cardiovascular disease among type 2 diabetic patients. Diabetes
Care. 30:1212–1218. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Silverman JF, O'Brien KF, Long S, Leggett
N, Khazanie PG, Pories WJ, Norris HT and Caro JF: Liver pathology
in morbidly obese patients with and without diabetes. Am J
Gastroenterol. 85:1349–1355. 1990.PubMed/NCBI
|
|
7
|
Marchesini G, Brizi M, Morselli-Labate AM,
Bianchi G, Bugianesi E, McCullough AJ, Forlani G and Melchionda N:
Association of nonalcoholic fatty liver disease with insulin
resistance. Am J Med. 107:450–455. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bugianesi E, McCullough AJ and Marchesini
G: Insulin resistance: A metabolic pathway to chronic liver
disease. Hepatology. 42:987–1000. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Korenblat KM, Fabbrini E, Mohammed BS and
Klein S: Liver, muscle, and adipose tissue insulin action is
directly related to intrahepatic triglyceride content in obese
subjects. Gastroenterology. 134:1369–1375. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tiikkainen M, Tamminen M, Hakkinen AM,
Bergholm R, Vehkavaara S, Halavaara J, Teramo K, Rissanen A and
Yki-Järvinen H: Liver-fat accumulation and insulin resistance in
obese women with previous gestational diabetes. Obes Res.
10:859–867. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chu MP, Klopfenstein BJ, Krisky CM,
Urbanski HF, Rooney WD, Kohama SG and Purnell JQ: Intrahepatic
lipid, not visceral or muscle fat, is correlated with insulin
resistance in older, female rhesus macaques. Obesity (Silver
Spring). 21:2021–2028. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rottiers V and Näär AM: MicroRNAs in
metabolism and metabolic disorders. Nat Rev Mol Cell Biol.
13:239–250. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liang H, Li Y, Luo RY and Shen FJ:
MicroRNA-215 is a potential prognostic marker for cervical cancer.
J Huazhong Univ Sci Technolog Med Sci. 34:207–212. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu F, You X, Chi X, Wang T, Ye L, Niu J
and Zhang X: Hepatitis B virus X protein mutant HBx Delta 127
promotes proliferation of hepatoma cells through up-regulating
miR-215 targeting PTPRT. Biochem Biophys Res Commun. 444:128–134.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Deng Y, Huang Z, Xu Y, Jin J, Zhuo W,
Zhang C, Zhang X, Shen M, Yan X, Wang L, et al: MiR-215 modulates
gastric cancer cell proliferation by targeting RB1. Cancer Lett.
342:27–35. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wijnhoven BP, Hussey DJ, Watson DI, Tsykin
A, Smith CM and Michael MZ; South Australian Oesophageal Research
Group, : MicroRNA profiling of Barrett's oesophagus and oesophageal
adenocarcinoma. Br J Surg. 97:853–861. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Karaayvaz M, Pal T, Song B, Zhang C,
Georgakopoulos P, Mehmood S, Burke S, Shroyer K and Ju J:
Prognostic significance of miR-215 in colon cancer. Clin Colorectal
Cancer. 10:340–347. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Facchinetti V, Ouyang W, Wei H, Soto N,
Lazorchak A, Gould C, Lowry C, Newton AC, Mao Y, Miao RQ, et al:
The mammalian target of rapamycin complex 2 controls folding and
stability of Akt and protein kinase C. EMBO J. 27:1932–1943. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yuan M, Pino E, Wu L, Kacergis M and
Soukas AA: Identification of Akt-independent regulation of Hepatic
lipogenesis by mammalian target of rapamycin (mTOR) complex 2. J
Biol Chem. 287:29579–29588. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Garcia-Martinez JM and Alessi DR: mTOR
complex 2 (mTORC2) controls hydrophobic motif phosphorylation and
activation of serum- and glucocorticoid-induced protein kinase 1
(SGK1). Biochem J. 416:375–385. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ikenoue T, Inoki K, Yang Q, Zhou X and
Guan KL: Essential function of TORC2 in PKC and Akt turn motif
phosphorylation, maturation and signalling. EMBO J. 27:1919–1931.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sarbassov DD, Guertin DA, Ali SM and
Sabatini DM: Phosphorylation and regulation of Akt/PKB by the
rictor-mTOR complex. Science. 307:1098–1101. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yang Q, Inoki K, Ikenoue T and Guan KL:
Identification of Sin1 as an essential TORC2 component required for
complex formation and kinase activity. Genes Dev. 20:2820–2832.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Guertin DA, Stevens DM, Thoreen CC, Burds
AA, Kalaany NY, Moffat J, Brown M, Fitzgerald KJ and Sabatini DM:
Ablation in mice of the mTORC components raptor, rictor, or mLST8
reveals that mTORC2 is required for signaling to Akt-FOXO and PKC
alpha but not S6K1. Dev Cell. 11:859–871. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Soukas AA, Kane EA, Carr CE, Melo JA and
Ruvkun G: Rictor/TORC2 regulates fat metabolism, feeding, growth,
and life span in caenorhabditis elegans. Genes Dev. 23:496–511.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Frias MA, Thoreen CC, Jaffe JD, Schroder
W, Sculley T, Carr SA and Sabatini DM: mSin1 is necessary for
Akt/PKB phosphorylation, and its isoforms define three distinct
mTORC2s. Curr Biol. 16:1865–1870. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
National Research Council (US) Committee
for the Update of the Guide for the Care and Use of Laboratory
Animals, . Guide for the Care and Use of Laboratory Animals. 8th.
National Academies Press (US); Washington, DC: 2011
|
|
29
|
Liu W, Cao H, Ye C, Chang C, Lu M, Jing Y,
Zhang D, Yao X, Duan Z, Xia H, et al: Hepatic miR-378 targets
p110alpha and controls glucose and lipid homeostasis by modulating
hepatic insulin signalling. Nat Commun. 5:56842014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kumashiro N, Erion DM, Zhang D, Kahn M,
Beddow SA, Chu X, Still CD, Gerhard GS, Han X, Dziura J, et al:
Cellular mechanism of insulin resistance in nonalcoholic fatty
liver disease. Proc Natl Acad Sci USA. 108:16381–16385. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Samuel VT, Liu ZX, Wang A, Beddow SA,
Geisler JG, Kahn M, Zhang XM, Monia BP, Bhanot S and Shulman GI:
Inhibition of protein kinase C epsilon prevents hepatic insulin
resistance in nonalcoholic fatty liver disease. J Clin Invest.
117:739–745. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Rines AK, Sharabi K, Tavares CD and
Puigserver P: Targeting hepatic glucose metabolism in the treatment
of type 2 diabetes. Nat Rev Drug Discov. 15:786–804. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Czech MP: Insulin action and resistance in
obesity and type 2 diabetes. Nat Med. 23:804–814. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Trajkovski M, Hausser J, Soutschek J, Bhat
B, Akin A, Zavolan M, Heim MH and Stoffel M: MicroRNAs 103 and 107
regulate insulin sensitivity. Nature. 474:649–653. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Li S, Chen X, Zhang H, Liang X, Xiang Y,
Yu C, Zen K, Li Y and Zhang CY: Differential expression of
microRNAs in mouse liver under aberrant energy metabolic status. J
Lipid Res. 50:1756–1765. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Park JH, Ahn J, Kim S, Kwon DY and Ha TY:
Murine hepatic miRNAs expression and regulation of gene expression
in diet-induced obese mice. Mol Cells. 31:33–38. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Petersen MC and Shulman GI: Roles of
diacylglycerols and ceramides in hepatic insulin resistance. Trends
Pharmacol Sci. 38:649–665. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Raddatz K, Turner N, Frangioudakis G, Liao
BM, Pedersen DJ, Cantley J, Wilks D, Preston E, Hegarty BD, Leitges
M, et al: Time-dependent effects of Prkce deletion on glucose
homeostasis and hepatic lipid metabolism on dietary lipid
oversupply in mice. Diabetologia. 54:1447–1456. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhao LP, Xu WT, Wang L, You T, Chan SP,
Zhao X and Yang XJ: Serum adropin level in patients with stable
coronary artery disease. Heart Lung Circ. 24:975–979. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Dijk W Dijk W, Beigneux AP, Larsson M,
Bensadoun A, Young SG and Kersten S: Angiopoietin-like 4 (ANGPTL4)
promotes intracellular degradation of lipoprotein lipase in
adipocytes. J Lipid Res. 57:1949. 2016.PubMed/NCBI
|
|
42
|
Zhang X, Yeung DC, Karpisek M, Stejskal D,
Zhou ZG, Liu F, Wong RL, Chow WS, Tso AW, Lam KS and Xu A: Serum
FGF21 levels are increased in obesity and are independently
associated with the metabolic syndrome in humans. Diabetes.
57:1246–1253. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wu HT, Lu FH, Ou HY, Su YC, Hung HC, Wu
JS, Yang YC, Wu CL and Chang CJ: The role of hepassocin in the
development of non-alcoholic fatty liver disease. J Hepatol.
59:1065–1072. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Lan F, Misu H, Chikamoto K, Takayama H,
Kikuchi A, Mohri K, Takata N, Hayashi H, Matsuzawa-Nagata N,
Takeshita Y, et al: LECT2 functions as a hepatokine that links
obesity to skeletal muscle insulin resistance. Diabetes.
63:1649–1664. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Farese RV Jr, Zechner R, Newgard CB and
Walther TC: The problem of establishing relationships between
hepatic steatosis and hepatic insulin resistance. Cell Metab.
15:570–573. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Brown JM, Betters JL, Lord C, Ma Y, Han X,
Yang K, Alger HM, Melchior J, Sawyer J, Shah R, et al: CGI-58
knockdown in mice causes hepatic steatosis but prevents
diet-induced obesity and glucose intolerance. J Lipid Res.
51:3306–3315. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Minehira K, Young SG, Villanueva CJ,
Yetukuri L, Oresic M, Hellerstein MK, Farese RV Jr, Horton JD,
Preitner F, Thorens B and Tappy L: Blocking VLDL secretion causes
hepatic steatosis but does not affect peripheral lipid stores or
insulin sensitivity in mice. J Lipid Res. 49:2038–2044. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Sun Z, Miller RA, Patel RT, Chen J, Dhir
R, Wang H, Zhang D, Graham MJ, Unterman TG, Shulman GI, et al:
Hepatic Hdac3 promotes gluconeogenesis by repressing lipid
synthesis and sequestration. Nat Med. 18:934–942. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Jordan SD, Krüger M, Willmes DM, Redemann
N, Wunderlich FT, Brönneke HS, Merkwirth C, Kashkar H, Olkkonen VM,
Böttger T, et al: Obesity-induced overexpression of miRNA-143
inhibits insulin-stimulated AKT activation and impairs glucose
metabolism. Nat Cell Biol. 13:434–446. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Zhou SW, Su BB, Zhou Y, Feng YQ, Guo Y,
Wang YX, Qi P and Xu S: Aberrant miR-215 expression is associated
with clinical outcome in breast cancer patients. Med Oncol.
31:2592014. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Zang Y, Wang T, Pan J and Gao F: miR-215
promotes cell migration and invasion of gastric cancer cell lines
by targeting FOXO1. Neoplasma. 64:579–587. 2017. View Article : Google Scholar : PubMed/NCBI
|
